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Abstracts / Biol Blood Marrow Transplant 19 (2013) S178eS193 S191herpetic neuralgia (n¼5), severe pain (n¼3), scarring (n¼1),
and motor weakness (n¼1); 2 patients required hospitaliza-
tion and 3 patients developed disseminated zoster.
Conclusions: Our limited retrospective analysis suggests
a signiﬁcant reduction in rates of post auto-HCT rates of VZV
infection with extended 12month antiviral prophylaxis. VZV
infection is a signiﬁcant complication post auto-HCT, and
extended prophylaxis appears to be safe and effective in this
setting.
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We report 35 patients who received high dose melphalan
and autologous stem cell transplantation for systemic AL
amyloidosis. Between Sep. 2006 and Jul. 2012, 35 patients
with AL amyloidosis were transplanted at Japanese Red Cross
Medical Center. Characteristics of patients were shown as
follows: median age; 54 (range 39-70), M/F¼15/20, major
organ involvement; heart 13, kidney 19, others 3 (liver 1,
trachea 1, peripheral nerve 1), median melphalan dose; 128
(range 50-200) mg/m2, median infused CD34+ cells; 2.67
(range 1.17-11.26) x 106/kg. Out of 35 patients, 28 are alive
after median follow up of 18.7 (range 2-68) months and two
and four years estimated overall survival were 84.6% and
66.6%, respectively. Four patients died of heart failure and
other three patients died of either gastrointestinal bleeding,
bacteremia, or malignancy. Four year estimated survival of
patients with cardiac involvement is 46.2% and is signiﬁ-
cantly lower as compared with that with others (69.2%).
Serum albumin increased (average 21%) in patients survived
more than 12months after ASCT. Serum free light chain (FLC)
was measured before and after ASCT in 7 patients, and of
those, FLC rapidly decreased after ASCT in 5 patients. Patients
without cardiac involvement showed satisfactory survival
with improvement of clinical symptom and serum albumin.
Careful patient selection and experienced management are
important especially for patients with cardiac involvement.
Serum FLCmay be useful for evaluating effectiveness of ASCT
and also for early detection of relapse.155
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Background: The use of plerixafor formobilization following
chemotherapy has not been extensively studied. We tested
the hypothesis that adding plerixafor to G-CSF after chemo-
therapywould increase the proportion of patientsmobilizing
the target number of hematopoietic progenitor cells in one
day to 75% from a historical value of 50%.Methods:Multiplemyeloma (MM) or lymphoma patients for
whom autologous stem cell transplantation was intended
were eligible. Patients were mobilized with chemotherapy
consisting of either cyclophosphamide (N¼16), DCEP (N¼1),
R-ICE (N¼10), CHOP (N¼2) or R-HyperCVAD (N¼5) with daily
administration of G-CSF at a dose of 10 mcg/kg/day starting
one day after the completion of chemotherapy. The per-
protocol plan was subcutaneous injection of 240 mcg/kg
plerixaforon theﬁrstdayonwhich theneutrophil countwas>
1500 cells/uL followed by apheresis the next day. G-CSF, pler-
ixafor and apheresis were repeated daily until 5 (lymphoma)
or 10 x 10E6 CD34+ cells/kg (myeloma) were collected.
Results: 17 MM and 28 lymphoma patients with a median
age of 57 (range 33-73) were enrolled. 33/45 subjects (76%)
collected the target number of CD34+ cells in one day. 12
subjects (7 MM and 5 lymphoma) with a median CD34+
count of 201 cells/uL began apheresis without plerixafor on
the ﬁrst day of monitoring and collected a median of 19 x
10E6 CD34+ cells/kg in one day. The remaining 33 patients
(10 MM and 23 lymphoma) received plerixafor with median
numbers of 30 CD34+ cells/uL, and 4100 neutrophils/uL that
increased to 95 CD34+ cells/uL and 24,799 neutrophils/uL the
next day. Plerixafor-treated subjects collected amedian of 7.8
x 10E6 CD34+ cells/kg; 22 (66%) collected the target number
in one day, while 6 (18%), 3 (9%), and 2 (6%) of the plerixafor-
treated subjects required 2, 3, or 4 days of apheresis,
respectively. Plerixafor was well tolerated, with 29 total AE,
and no SAE recorded during mobilization and/or apheresis.
Seven grade 3/4 AE were seen, including thrombocytopenia
(4), fatigue (1), anemia (1) and hypokalemia (1). 44/45
enrolled subjects underwent high-dose chemotherapy and
re-infusion of CD34+ cells. Plerixafor-treated and non-pler-
ixafor treated transplant recipients promptly engrafted with
neutrophil and platelets at median of 12 and 16 days,
respectively, with stable hematopoiesis noted at 12 months.
Conclusions: Plerixafor administration after chemotherapy
for ASC mobilization is feasible and well tolerated. A greater
percentage (76%) of enrolled subjects collected more than
the target number of cells in one day of apheresis compared
with a historical cohort of patients mobilized with G-CSF
after chemotherapy (54%; P < 0.03). Daily monitoring of
blood counts after chemotherapy is needed to appropriately
schedule plerixafor administration. One-fourth of chemo-
therapy-treated patients mobilized an adequate number of
CD34+ in one day without plerixafor.156
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Bone marrow is a highly innervated tissue with nerve ﬁbers
terminating in association with stromal cells. Bone marrow
neuropathy has been associated with abnormal hematopoi-
etic stem cell (HSC) trafﬁcking and activity in animal models
of diabetes. There is also evidence that granulocyte colony-
stimulating factor (G-CSF) mediates its mobilizing effect on
HSC through modulation of norepinephrine release from
adrenergic neurons. Therefore, we hypothesized that pre-
Table 1
Immune and Clinical Parameters
Standard group
(N¼23)
Study group
(N¼14)
Med (range) Median (range)
CD 34+ cells collected (x 10^6/kg) 11.7 (5.1 - 20.7) 13.0 (10.1 -28.0)
CD 34+ cells infused (x 10^6/kg) 5.0 (3.2 - 8.3) 9.7 (7.0 e 14.0)
Duration of ANC < 500 k/mL
(days)
4 (3 - 9) 4 (3 - 5)
Time to neutrophil engraftment
(days)
10 (8 - 14) 10 (9 - 11)
Duration of ALC< 500 k/mL (days) 14 (5 - 22) 14 (12 - 23)
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HSCmobilization and/or time to engrafment in the context of
ASCT for lymphoma. We retrospectively identiﬁed 46 ASCT
patients, all of whom were mobilized with G-CSF. Twenty
four patients were identiﬁed as poor mobilizers (PM) based
on the need for rescue pleriaxfor after mobilization failure,
while 22 patients were identiﬁed as good mobilizers (GM)
based on the ability to collect the target HSC dose within two
days of apheresis. We compared the clinical and immuno-
histochemical characteristics between the two groups. The
adequacy of bone marrow innervation was determined by
semiquantitative immunohistochemistical scoring of tyro-
sine hydroxylase positive (TH+) nerve terminals in pre-ASCT
bone marrow core biopsies. The mean TH scores were 2.33
for PM vs. 1.32 for GM (p¼0.2). There was a non signiﬁcant
trend towards a longer time to neutrophil/platelet engraft-
ment when no TH+ nerve terminals were identiﬁed vs. any
TH+ terminals identiﬁed (11/11.4 vs.10.8/10.7 days respec-
tively). HSC from the group with no TH+ nerve terminals had
less colony forming units (CFU) compared to the group that
had any TH+ terminals identiﬁed (7.1 vs. 10.4 x 106 CFU/kg, P
¼ .58). Also, the group with no TH+ nerve terminals had
lower peripheral blood CD34+ cell counts, before collection
and after G-CSF priming, compared to the group with any
TH+ terminals identiﬁed (18.3 vs. 28.7/mm3, P ¼ .66). As
expected, the time to neutrophil/platelet engrafment was
higher in the PM compared to the GM group (11.5/13.3 vs.
10.3/8.6, P ¼ .004/P < 0.0001, respectively). Owing to the
small sample size, we can't draw deﬁnite conclusions about
the impact of bone marrow neuropathy on HSC mobilization
and ASCT outcomes but we observed a trend toward higher
HSC mobilization, longer time to engraftment and decreased
HSC CFU capacity in patients with evidence of bone marrow
neuropathy. This is consistent with what other investigators
have demonstrated in animal models. Failure of G-CSF
mobilization was associated with longer time to neutrophil
and platelet engraftment in patients with lymphoma
undergoing ASCT.Time to lymphocyte engraftment
(days)
14 (9-21) 13 (11-22)
Time to PLT engraftment (days) 13 (0-17) 13.5 (10-20)
# of RBC Transfusions 0 (0 - 8) 0 (0 - 3)
# of PLT Transfusions 2 (0 - 12) 1 (1 - 4)
Days of T  38 deg C 1 (0-8) 0 (0-7)
Days on empiric/directed
antibiotics
5 (0 - 28) 0 (0 - 14)
Infections, N (%) 7 (30) 1 (7)
Days of diarrhea  500cc 0 (0-3) 0 (0-7)
Pts with ES, N (%) 0 (0) 3 (21)
Pts with infusion reactions, N (%) 2 (9) 0
Duration of hospitalization (days) 17 (13 - 36) 15 (13 - 19)157
Fractionated Stem Cell Infusions for Patients with
Multiple Myeloma Undergoing Autologous Stem Cell
Transplant
Kevin Wood 1, Sergio A. Giralt 2, Guenther Koehne 2,
David Chung 3, Hani Hassoun 4, Nikoletta Lendvai 4,
Alexander Lesokhin 4, Elizabeth Hoover 5, Sean Devlin 6,
Heather Landau 7. 1Weill Cornell Medical Center; 2 Department
of Medicine, Adult Bone Marrow Transplant Service, Memorial
Sloan-Kettering Cancer Center, New York, NY; 3Memorial
Sloan-Kettering Cancer Center, New York, NY; 4Memorial
Sloan-Kettering Cancer Center; 5Medicine- Adult Bone Marrow
Transplant, Memorial Sloan-Kettering Cancer Center, New
York, NY; 6 Department of Biostatistics, Memorial Sloan-
Kettering Cancer Center, New York, NY; 7 TBD
Background: High dose MEL with auto SCT is an established
therapeutic modality for MM. Although effective, it is associ-
ated with signiﬁcant symptom burden due to the obligate
periodofneutropeniaand increased riskof infection. Inanimal
models, infusing stemcells (SC) overa periodof days enhances
immune reconstitution (Felﬂy H, et al. 2009). Multiple SC
infusions could reduce the period of neutropenia and enhance
immune recovery resulting in a better tolerated procedure.
Methods: We are conducting a phase II trial of multiple
fractionated auto SC infusions after high-dose MEL. We
compared initial engraftment kinetics after high-doseMEL of
the ﬁrst 14 pts to receive multiple infusions (Days 0, +2, +4,+6) (study group) to 23 pts receiving the standard single SC
infusion (Day 0) (standard group). Pegﬁlgrastimwas given on
Day +1 and SCT was between October 2011 and July 2012 in
all pts.
Results: Table 1. Similar numbers of SCs were collected in
both groups. The number of SCs infused was 9.7 x 10^6
CD34+ cells/kg vs 5.0 x 10^6 CD34+ cells/kg in study and
standard pts. To date, the median duration of neutropenia
(days ANC < 500) and lymphopenia (days ALC < 500), and
days to neutrophil, lymphocyte and PLT engraftment were
similar. There were no signiﬁcant differences in the
number of red cell or PLT transfusions, days of fever,
diarrhea, empiric antibiotics or documented infections.
Despite multiple SC infusions, none of the pts in the study
group experienced infusion reaction. Engraftment
syndrome (ES) occurred in 3/14 of study pts. Duration of
hospitalization was 15 days in study pts vs 17 days in the
concurrent control group (P ¼ 0.01).
Conclusions:Multiple SC infusions after high doseMEL inpts
with MM were not associated with increased adverse effects
from DMSO or unexpected frequency of ES. Fractionating SCs
over a period of daysmay result in less antibiotic use, reduced
infection and was associated with shorter hospital stay. We
continue to collect pt reported symptom scores to determine
if we can improve pt experience during SCT.158
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